MX2010004556A - Formulacion farmaceutica de acido clavulanico. - Google Patents

Formulacion farmaceutica de acido clavulanico.

Info

Publication number
MX2010004556A
MX2010004556A MX2010004556A MX2010004556A MX2010004556A MX 2010004556 A MX2010004556 A MX 2010004556A MX 2010004556 A MX2010004556 A MX 2010004556A MX 2010004556 A MX2010004556 A MX 2010004556A MX 2010004556 A MX2010004556 A MX 2010004556A
Authority
MX
Mexico
Prior art keywords
compositions
release
pharmaceutical formulation
clavulanic acid
stabilized
Prior art date
Application number
MX2010004556A
Other languages
English (en)
Spanish (es)
Inventor
Young Bok Lee
Deog Joong Kim
Chang Ho Ahn
Edward Carl Scholtz
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of MX2010004556A publication Critical patent/MX2010004556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2010004556A 2007-10-26 2008-10-24 Formulacion farmaceutica de acido clavulanico. MX2010004556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99607907P 2007-10-26 2007-10-26
PCT/US2008/012126 WO2009055038A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Publications (1)

Publication Number Publication Date
MX2010004556A true MX2010004556A (es) 2010-07-01

Family

ID=40579869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004556A MX2010004556A (es) 2007-10-26 2008-10-24 Formulacion farmaceutica de acido clavulanico.

Country Status (11)

Country Link
US (1) US20090270358A1 (enExample)
EP (1) EP2214680A4 (enExample)
JP (1) JP2011500811A (enExample)
KR (1) KR20100101574A (enExample)
CN (1) CN101918004A (enExample)
AU (1) AU2008317315A1 (enExample)
BR (1) BRPI0818702A2 (enExample)
CA (1) CA2703224A1 (enExample)
IL (1) IL205313A0 (enExample)
MX (1) MX2010004556A (enExample)
WO (1) WO2009055038A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR101628095B1 (ko) 2010-10-18 2016-06-08 현대자동차 주식회사 저압 ｅｇｒ시스템 제어장치 및 방법
CN102058584B (zh) * 2010-12-30 2012-01-25 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2015153984A2 (en) 2014-04-04 2015-10-08 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
BR0013366A (pt) 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US7166626B2 (en) 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
PE20060489A1 (es) * 2004-08-13 2006-06-19 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CA2644911A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
JP2011500811A (ja) 2011-01-06
IL205313A0 (en) 2010-12-30
CN101918004A (zh) 2010-12-15
EP2214680A1 (en) 2010-08-11
WO2009055038A1 (en) 2009-04-30
AU2008317315A1 (en) 2009-04-30
EP2214680A4 (en) 2010-12-29
BRPI0818702A2 (pt) 2015-04-22
CA2703224A1 (en) 2009-04-30
KR20100101574A (ko) 2010-09-17
US20090270358A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
MY143795A (en) Tetrahydropyridoindole derivatives
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2005112633A3 (en) Compounds and compositions for delivering active agents
IL179718A0 (en) Pharmaceutical composition containing irbesartan
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
WO2007014124A3 (en) High drug load formulations and dosage forms
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
WO2009088673A3 (en) Pharmaceutical composition
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
WO2007121471A3 (en) Dialkyl ether delivery agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal